Crossmark

Neoadjuvant dose-dense anthracycline and cyclophosphamide in combination with carboplatin, paclitaxel, and pembrolizumab for triple-negative breast cancer: a systematic review and meta-analysis

Crossref DOI link: https://doi.org/10.1007/s10549-025-07746-y

Published Online: 2025-06-13

Published Print: 2025-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Liutti, Vitor Teixeira https://orcid.org/0000-0003-1199-0153
do Vale, David Laios

de Souza, Bruno Lins

Manea, Rafael Ricci Ferrari

Araújo, Daniel Vilarim https://orcid.org/0000-0002-7013-5408
License Information

Text and Data Mining valid from 2025-06-13

Version of Record valid from 2025-06-13
More Information

Article History

Received: 23 February 2025

Accepted: 20 May 2025

First Online: 13 June 2025

Declarations

:

: The authors did not receive support from any organization for the submitted work. The authors declare no competing non-financial interests but the following competing financial interests: VTL has received speaker and consultant honoraria from Roche, Novartis AstraZeneca, Janssen, MSD, Pfizer, BMS and Daiichi Sankyo. Institutional research grant from: Roche, Novartis, AstraZeneca, Janssen, MSD, Lilly, Incyte, Seagen, Huyabio, Beigene, Tolmar, Daiichi Sankyo. RRFM has received speaker honoraria from Bayer. DVA has received speaker and consultant honoraria from MSD, Libbs, AstraZeneca, Tersera. DLS and BLS declare they have no financial interests.

Document is current

Any future updates will be listed below